The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth
The report titled “The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth” provides a comprehensive analysis on the Anti Cancer Drug market in the US covering various aspects such as market size of the industry, market segmentation by Patented and Generic drugs, by type of cancer (blood cancer, breast cancer, lung cancer, pancreatic cancer, colon cancer) and by Oral and Injectable Drugs. The report also provides statistics and information on the government regulations, growth drivers and market shares of major players and brands in the market. The report also entails competitive landscape and profiles of the major players operating in the market. The future projections are included to provide an insight on the prospects in the US Anti Cancer Drug Market.
The US Anti Cancer Drug market is the largest market in the world which has registered a positive growth rate over the period. The rising growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing number of cancer cases although many major drugs which lost their patent protection has hampered the growth of the market. The US Anti Cancer Drug Market has recorded a 5 year CAGR of 6.50% over the period. The sales of anti cancer drugs in the US grew from USD ~ billion in 2008 to USD ~ billion in 2013.
The Breast Cancer Drug Market is one of largest markets in terms of breast cancer drug sales with a global share of 59% and was valued at USD ~ billion in 2013. The breast cancer drug market though had a busy pipeline but has been mainly driven by sales of three major drugs namely Arimidex, Herceptin and Afinitor in recent years. Pancreatic cancer is one of the most researched segments as it cannot be diagnosed in a time leading to a fall in its survival rates. Avastin, Rituxan, Herceptin and Alimta were among the world’s top selling anti cancer drugs and each recorded sales above USD ~ million in the US in 2013.
The anti-cancer drug market of US is highly fragmented. The major players are continuously adopting diverse strategies in order to maintain their competitive edge especially when it comes to competition from generic drugs. Roche is the largest company in the US in terms of anti cancer drugs sales. The company held a market share of ~% and recorded sales of USD ~ million.
The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with projected sales of USD ~ billion in 2018. It is estimated that the research and development productivity will increase and will trigger the growth in the market. The companies will focus on developing pharmaceutical drugs for personalized healthcare.
KEY TOPICS COVERED IN THE REPORT
The US Anti Cancer Drug market is the largest market in the world which has registered a positive growth rate over the period. The rising growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing number of cancer cases although many major drugs which lost their patent protection has hampered the growth of the market. The US Anti Cancer Drug Market has recorded a 5 year CAGR of 6.50% over the period. The sales of anti cancer drugs in the US grew from USD ~ billion in 2008 to USD ~ billion in 2013.
The Breast Cancer Drug Market is one of largest markets in terms of breast cancer drug sales with a global share of 59% and was valued at USD ~ billion in 2013. The breast cancer drug market though had a busy pipeline but has been mainly driven by sales of three major drugs namely Arimidex, Herceptin and Afinitor in recent years. Pancreatic cancer is one of the most researched segments as it cannot be diagnosed in a time leading to a fall in its survival rates. Avastin, Rituxan, Herceptin and Alimta were among the world’s top selling anti cancer drugs and each recorded sales above USD ~ million in the US in 2013.
The anti-cancer drug market of US is highly fragmented. The major players are continuously adopting diverse strategies in order to maintain their competitive edge especially when it comes to competition from generic drugs. Roche is the largest company in the US in terms of anti cancer drugs sales. The company held a market share of ~% and recorded sales of USD ~ million.
The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with projected sales of USD ~ billion in 2018. It is estimated that the research and development productivity will increase and will trigger the growth in the market. The companies will focus on developing pharmaceutical drugs for personalized healthcare.
KEY TOPICS COVERED IN THE REPORT
- The market size of the US anti cancer drug market on the basis of sales, number of drugs in development and number of drugs approved.
- The breast cancer, lung cancer, pancreatic cancer, colon cancer, blood and brain cancer drug market
- Market segmentation of the US anti cancer drug market on the basis of Type of Therapies, Orals and Injectables and by Generic and Patented Drugs
- Government Regulations in the US Anti Cancer Drug Market.
- Competitive landscape and detailed company profiles of the major players operating in the pesticides business in US
- Revenues of Major Players in US Anti Cancer Drugs Market.
- Future outlook and projections of US Anti Cancer Drugs Market, on the basis of anti cancer drug sales in the US.
1. ANTI-CANCER DRUGS MARKET INTRODUCTION
1.1. Global Scenario
1.2. Domestic Scenario
1.2.1. Overview
1.2.2. Research & Development Pipeline
Acquisition of Potential Compounds
Drug Screening and Pre Clinical Pharmacology
Clinical Trials
2. PREVALENCE OF DIFFERENT TYPES OF CANCERS IN THE US
2.1. By Number of New Cancer Cases, 2008 -2013
2.2. By Major Types of Cancer, 2008-2013
Cases of Breast Cancer
Cases of Pancreatic Cancer
Cases of Colon Cancer
Cases of Lung Cancer
Cases of Blood Cancer
Cases of Brain Cancer
3. THE US ANTI-CANCER DRUG MARKET SIZE
3.1. By Industry Sales, 2008-2013
3.2. By Number of Drugs Approved, 2008-2013
3.3. By Number of Cancer Drugs in Development, 2009 -2013
4. THE US ANTI-CANCER DRUG MARKET SEGMENTATION
4.1. By Types of Cancers (Blood, Breast, Colon, Lung, brain and Pancreatic Cancer), 2010-2013
4.2. By Oral Drugs and Injectables, 2013
4.3. By Cost of Therapies, 2013
Chemotherapy
Stem Cell Transplant
Targeted therapy
Immunotherapy
Hormone Therapy
4.4. By Generic and Patented Drugs, 2013
5. THE US BLOOD CANCER DRUG MARKET INTRODUCTION
5.1. The US Blood Cancer Drug Market Size, 2008-2013
Sales of Major Brain-Cancer Treatment Drugs (Rituxan, Revlimid, Velcade, Sprycel, Vidaza), 2008-2013
5.2. By Treatment and Side Effects
Treatment Cycle
Side Effects
5.3. By Patents and Expiry
6. THE US BREAST CANCER DRUGS MARKET INTRODUCTION
6.1. The US Breast Cancer Drugs Market Size, 2008-2013
By Sales of Major Cancer Drugs, 2008-2013
6.2. Treatment Process and Side Effects
Treatment Process
Side Effects
6.3. Patents and Expiry
7. THE US COLON CANCER DRUGS MARKET INTRODUCTION
7.1. The US Colon Cancer Drug Market Size, 2009-2013
Sales of Major Anti-Colon Cancer Drugs in The US, 2009-2013
7.2. Treatment and Side Effects
Treatment Cycle
Side Effects
7.3. Patents and Expiry
8. THE US BRAIN CANCER DRUGS MARKET INTRODUCTION
8.1. The US Brain Cancer Drugs Market Size, 2009-2013
Sales of Major Brain-Cancer Drugs in the US, 2009-2013
8.2. By Treatment and Side Effects
Treatment Cycle
Side Effects
8.3. By Patents and Expiry
9. THE US LUNG CANCER DRUGS MARKET INTRODUCTION
9.1. The US Lung Cancer Drugs Market Size, 2008-2013
9.1.1. Sales of Major Cancer Drugs, 2008-2013
9.2. By Small Cell Lung Cancer and Non Small Cell Lung Cancer, 2013
9.3. Treatment Process and Side Effects
The Treatment Cycle of Lung Cancer
Side Effects
9.4. Patents and Expiry
10. THE US PANCREATIC CANCER DRUGS MARKET INTRODUCTION
10.1. The US Pancreatic Cancer Drugs Market Size, 2008-2013
Sales of Major Pancreatic Cancer Drugs in the US, 2008-2013
10.2. Treatment Process and Side Effects
Treatment Cycle of Pancreatic Cancer
Side Effects
10.3. Patents and Expiry
11. TRENDS AND DEVELOPMENTS
12. REGULATIONS IN THE US ANTI-CANCER DRUG MARKET
Federal and State Regulations
13. SWOT ANALYSIS
14. GROWTH DRIVERS AND RESTRAINTS
14.1. Growth Drivers
14.2. Restraints
15. THE US ANTI-CANCER DRUGS INDUSTRY COMPETITIVE LANDSCAPE
15.1. Market Share of Major Players by Revenue, 2010- 2013
15.2. Sales of Major Brands, Patents and Comparative Analysis of Major Pharmaceutical Companies, 2013
16. COMPANY PROFILES
16.1. Pfizer
16.1.1. Business Overview
16.1.2. Business Strategies
16.1.3. Financial Performance, 2009-2013
Anti-cancer Drug profile
Cancer Drug Pipeline
16.2. Novartis
16.2.1. Business Overview
16.2.2. Business Strategies
16.2.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug pipeline
16.3. Roche
16.3.1. Business Overview
16.3.2. Business Strategies
16.3.3. Financial Performance, 2010-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.4. Astra Zeneca
16.4.1. Business Overview
16.4.2. Business Strategies
16.4.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.5. Bristol-Myers Squibb
16.5.1. Business Overview
16.5.2. Business Strategies
16.5.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.6. Amgen
16.6.1. Business Overview
16.6.2. Business Strategies
16.6.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.7. Merck & Company
16.7.1. Business Overview
16.7.2. Business Strategies
16.7.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug pipeline
16.8. Celgene
16.8.1. Business Overview
16.8.2. Business Strategies
16.8.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.9. Sanofi-Aventis
16.9.1. Business Overview
16.9.2. Business Strategies
16.9.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.10. Eli Lilly
16.10.1. Business Overview
16.10.2. Business Strategies
16.10.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.11. GlaxoSmithKline
16.11.1. Business Overview
16.11.2. Business Strategies
16.11.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
17. THE US ANTI-CANCER DRUG MARKET FUTURE OUTLOOK
Overall Market Predictions, 2014 - 2018
Role of the Government in the Future
Competition Expected to Evolve in Future
17.1. Cause and Effect Relationship between Independent and Dependent Factors
17.2. The US Anti-Cancer Drug Market Future Projections by Cancer Types, 2014-2018
17.3. Future Projections by Generic and Patented Drugs, 2018
18. MACRO-ECONOMIC FACTORS AFFECTING THE US ANTI-CANCER DRUGS MARKET
18.1. National Healthcare Spending, 2008-2018
18.2. Upper Class Population of the US, 2008-2018
18.3. Number of Oncologists in the US, 2008-2018
18.4. Consumer Expenditure on Healthcare, 2008-2018
19. APPENDIX
19.1. Market Definition
19.2. Abbreviations
19.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Final Conclusion
19.4. Disclaimer
1.1. Global Scenario
1.2. Domestic Scenario
1.2.1. Overview
1.2.2. Research & Development Pipeline
Acquisition of Potential Compounds
Drug Screening and Pre Clinical Pharmacology
Clinical Trials
2. PREVALENCE OF DIFFERENT TYPES OF CANCERS IN THE US
2.1. By Number of New Cancer Cases, 2008 -2013
2.2. By Major Types of Cancer, 2008-2013
Cases of Breast Cancer
Cases of Pancreatic Cancer
Cases of Colon Cancer
Cases of Lung Cancer
Cases of Blood Cancer
Cases of Brain Cancer
3. THE US ANTI-CANCER DRUG MARKET SIZE
3.1. By Industry Sales, 2008-2013
3.2. By Number of Drugs Approved, 2008-2013
3.3. By Number of Cancer Drugs in Development, 2009 -2013
4. THE US ANTI-CANCER DRUG MARKET SEGMENTATION
4.1. By Types of Cancers (Blood, Breast, Colon, Lung, brain and Pancreatic Cancer), 2010-2013
4.2. By Oral Drugs and Injectables, 2013
4.3. By Cost of Therapies, 2013
Chemotherapy
Stem Cell Transplant
Targeted therapy
Immunotherapy
Hormone Therapy
4.4. By Generic and Patented Drugs, 2013
5. THE US BLOOD CANCER DRUG MARKET INTRODUCTION
5.1. The US Blood Cancer Drug Market Size, 2008-2013
Sales of Major Brain-Cancer Treatment Drugs (Rituxan, Revlimid, Velcade, Sprycel, Vidaza), 2008-2013
5.2. By Treatment and Side Effects
Treatment Cycle
Side Effects
5.3. By Patents and Expiry
6. THE US BREAST CANCER DRUGS MARKET INTRODUCTION
6.1. The US Breast Cancer Drugs Market Size, 2008-2013
By Sales of Major Cancer Drugs, 2008-2013
6.2. Treatment Process and Side Effects
Treatment Process
Side Effects
6.3. Patents and Expiry
7. THE US COLON CANCER DRUGS MARKET INTRODUCTION
7.1. The US Colon Cancer Drug Market Size, 2009-2013
Sales of Major Anti-Colon Cancer Drugs in The US, 2009-2013
7.2. Treatment and Side Effects
Treatment Cycle
Side Effects
7.3. Patents and Expiry
8. THE US BRAIN CANCER DRUGS MARKET INTRODUCTION
8.1. The US Brain Cancer Drugs Market Size, 2009-2013
Sales of Major Brain-Cancer Drugs in the US, 2009-2013
8.2. By Treatment and Side Effects
Treatment Cycle
Side Effects
8.3. By Patents and Expiry
9. THE US LUNG CANCER DRUGS MARKET INTRODUCTION
9.1. The US Lung Cancer Drugs Market Size, 2008-2013
9.1.1. Sales of Major Cancer Drugs, 2008-2013
9.2. By Small Cell Lung Cancer and Non Small Cell Lung Cancer, 2013
9.3. Treatment Process and Side Effects
The Treatment Cycle of Lung Cancer
Side Effects
9.4. Patents and Expiry
10. THE US PANCREATIC CANCER DRUGS MARKET INTRODUCTION
10.1. The US Pancreatic Cancer Drugs Market Size, 2008-2013
Sales of Major Pancreatic Cancer Drugs in the US, 2008-2013
10.2. Treatment Process and Side Effects
Treatment Cycle of Pancreatic Cancer
Side Effects
10.3. Patents and Expiry
11. TRENDS AND DEVELOPMENTS
12. REGULATIONS IN THE US ANTI-CANCER DRUG MARKET
Federal and State Regulations
13. SWOT ANALYSIS
14. GROWTH DRIVERS AND RESTRAINTS
14.1. Growth Drivers
14.2. Restraints
15. THE US ANTI-CANCER DRUGS INDUSTRY COMPETITIVE LANDSCAPE
15.1. Market Share of Major Players by Revenue, 2010- 2013
15.2. Sales of Major Brands, Patents and Comparative Analysis of Major Pharmaceutical Companies, 2013
16. COMPANY PROFILES
16.1. Pfizer
16.1.1. Business Overview
16.1.2. Business Strategies
16.1.3. Financial Performance, 2009-2013
Anti-cancer Drug profile
Cancer Drug Pipeline
16.2. Novartis
16.2.1. Business Overview
16.2.2. Business Strategies
16.2.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug pipeline
16.3. Roche
16.3.1. Business Overview
16.3.2. Business Strategies
16.3.3. Financial Performance, 2010-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.4. Astra Zeneca
16.4.1. Business Overview
16.4.2. Business Strategies
16.4.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.5. Bristol-Myers Squibb
16.5.1. Business Overview
16.5.2. Business Strategies
16.5.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.6. Amgen
16.6.1. Business Overview
16.6.2. Business Strategies
16.6.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.7. Merck & Company
16.7.1. Business Overview
16.7.2. Business Strategies
16.7.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug pipeline
16.8. Celgene
16.8.1. Business Overview
16.8.2. Business Strategies
16.8.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.9. Sanofi-Aventis
16.9.1. Business Overview
16.9.2. Business Strategies
16.9.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.10. Eli Lilly
16.10.1. Business Overview
16.10.2. Business Strategies
16.10.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
16.11. GlaxoSmithKline
16.11.1. Business Overview
16.11.2. Business Strategies
16.11.3. Financial Performance, 2009-2013
Anti-Cancer Drug Profile
Cancer Drug Pipeline
17. THE US ANTI-CANCER DRUG MARKET FUTURE OUTLOOK
Overall Market Predictions, 2014 - 2018
Role of the Government in the Future
Competition Expected to Evolve in Future
17.1. Cause and Effect Relationship between Independent and Dependent Factors
17.2. The US Anti-Cancer Drug Market Future Projections by Cancer Types, 2014-2018
17.3. Future Projections by Generic and Patented Drugs, 2018
18. MACRO-ECONOMIC FACTORS AFFECTING THE US ANTI-CANCER DRUGS MARKET
18.1. National Healthcare Spending, 2008-2018
18.2. Upper Class Population of the US, 2008-2018
18.3. Number of Oncologists in the US, 2008-2018
18.4. Consumer Expenditure on Healthcare, 2008-2018
19. APPENDIX
19.1. Market Definition
19.2. Abbreviations
19.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Final Conclusion
19.4. Disclaimer
LIST OF FIGURES
Figure 1: Global Sales of Anti-Cancer Drugs in USD Billion, 2009-2013
Figure 2: Anti-cancer Drug Development and Approval Process in the US
Figure 3: US Anti-Cancer Drugs Market Size on the Basis of Industry Revenue in USD Million, 2008-2013
Figure 4: Number of Anti-Cancer Drugs in Development in the US, 2009-2013
Figure 5: Revenue of Pfizer from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 6: Revenues of Novartis from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 7: Revenues of Roche from Sales Anti-Cancer Drugs in the US in USD Million, 2010-2013
Figure 8: Revenues of Astra Zeneca from Sales Anti-Cancer Drugs in the US in USD Million, 2009-2013
Figure 9: Revenues of Bristol-Myers Squibb from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 10: Revenues of Amgen from Sales Anticancer Drugs in the US in USD Million, 2009-2013
Figure 11: Revenues of Merck and Company from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 12: Revenues of Celgene from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 13: Revenues of Sanofi-Aventis from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 14: Revenues of Eli-Lilly from Sales of Anti-cancer Drug in the US in USD Million, 2009-2013
Figure 15: Revenues from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 16: The US Anti-cancer Drug Industry Future Projections on the Basis of Sales in USD Million, 2014-2018
Figure 17: The US Anti-cancer Drug Industry Future Projections by Generic and Patented Drugs on the Basis of Revenue Contribution in Percentage, 2018
Figure 18: US National Healthcare Spending in USD Billion, 2008-2018
Figure 19: Upper Class Population of US in Thousand, 2008-2018
Figure 20: Number of Oncologists in US in Thousand, 2008-2018
Figure 21: Consumer Expenditure on Healthcare in the US in USD Million, 2008-2018
Figure 1: Global Sales of Anti-Cancer Drugs in USD Billion, 2009-2013
Figure 2: Anti-cancer Drug Development and Approval Process in the US
Figure 3: US Anti-Cancer Drugs Market Size on the Basis of Industry Revenue in USD Million, 2008-2013
Figure 4: Number of Anti-Cancer Drugs in Development in the US, 2009-2013
Figure 5: Revenue of Pfizer from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 6: Revenues of Novartis from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 7: Revenues of Roche from Sales Anti-Cancer Drugs in the US in USD Million, 2010-2013
Figure 8: Revenues of Astra Zeneca from Sales Anti-Cancer Drugs in the US in USD Million, 2009-2013
Figure 9: Revenues of Bristol-Myers Squibb from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 10: Revenues of Amgen from Sales Anticancer Drugs in the US in USD Million, 2009-2013
Figure 11: Revenues of Merck and Company from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 12: Revenues of Celgene from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 13: Revenues of Sanofi-Aventis from Sales Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 14: Revenues of Eli-Lilly from Sales of Anti-cancer Drug in the US in USD Million, 2009-2013
Figure 15: Revenues from Sales of Anti-cancer Drugs in the US in USD Million, 2009-2013
Figure 16: The US Anti-cancer Drug Industry Future Projections on the Basis of Sales in USD Million, 2014-2018
Figure 17: The US Anti-cancer Drug Industry Future Projections by Generic and Patented Drugs on the Basis of Revenue Contribution in Percentage, 2018
Figure 18: US National Healthcare Spending in USD Billion, 2008-2018
Figure 19: Upper Class Population of US in Thousand, 2008-2018
Figure 20: Number of Oncologists in US in Thousand, 2008-2018
Figure 21: Consumer Expenditure on Healthcare in the US in USD Million, 2008-2018
LIST OF TABLES
Table 1: Average Cost of Treatment of Cancer in USD
Table 2: Anti-cancer Drugs in Pipeline
Table 3: Number of New Cancer Cases in US, 2008-2013
Table 4: Number of New Cases of Cancer in the US by Types of Cancers, 2008-2013
Table 5: Number of Anti Cancer Drugs Approved in the US, 2008-2013
Table 6: The US Anti Cancer Drug Market Segmentation by Types of Cancer by Industry Revenue in USD Million, 2010-2013
Table 7: Prices of Injectable Drugs in US by Cycle in USD, 2013
Table 8: Prices of Oral Drugs in US by Cycle in USD
Table 9: Cost of Cancer Therapies in USD, 2013
Table 10: Drugs Used for the Different Types of Cancer Therapies
Table 11: The US Anti Cancer Drug Market Segmentation by Generic and Patented Drugs on the Basis of Sales in USD Million and Contribution in Percentage, 2013
Table 12: Cost of Generic Drugs in USD, 2012
Table 13: Sales of Major Blood Cancer Drugs in USD Million, 2008-2013
Table 14: Prices of Major Blood Cancer Drugs per Cycle in USD, 2013
Table 15: Leukemia Survival by Stage in Percentage
Table 16: Approval and Expiry of Blood Cancer Drugs
Table 17: Sales of Major Breast Cancer Drugs in the US in USD Million, 2008-2013
Table 18: Prices of Major Breast Cancer Drugs per Cycle in USD, 2013
Table 19: Breast Cancer Survival by Stage in Percentage
Table 20: Approval and Expiry Periods of Major Breast Cancer Drugs in the US
Table 21: Sales of Major Colon Cancer Drugs in the US in USD Million, 2009-2013
Table 22: Prices of Major Colon Cancer Drugs per Cycle in USD, 2013
Table 23: Colon Cancer Survival Rate by Stage in Percentage
Table 24: Approvals and Expiry for Colon Cancer Drugs
Table 25: Sales of Major Brain Cancer Drugs in USD Million, 2009-2013
Table 26: Prices of Major Brain Cancer Drugs per Cycle in USD, 2013
Table 27: Brain Cancer Survival by Age in Percentage
Table 28: Approval and Expiry for Brain Cancer Drugs
Table 29: Sales of Major Lung Cancer Drugs in the US in USD Million, 2008-2013
Table 30: Prices of Major Lung Cancer Drugs per Cycle in USD, 2013
Table 31: The US Anti- Lung Cancer Drugs Market Segmentation by Small Cell Lung Cancer and Non Small Cell Lung Cancer on the Basis of Revenue Contribution in USD Million & Percentage, and Incidence Rates in the US, 2013
Table 32: Lung Cancer Survival by Stage
Table 33: Approval and Expiry Period of Major Lung Cancer Drugs in the US
Table 34: Sales of Major Pancreatic Cancer Drugs in USD Million, 2008-2013
Table 35: Prices of Major Pancreatic Cancer Drugs per Cycle in USD, 2013
Table 36: Exocrine Pancreatic Cancer Survival by Stage in Percentage
Table 37: Neuro-Endocrine Pancreatic Cancer Treated with Surgery Survival by Stage in Percentage
Table 38: Approval and Expiry Period of Major Pancreatic Cancer Drugs in the US
Table 39: US Anti-cancer Drug Market SWOT Analysis
Table 40: Market Shares of Major players by Revenue Contribution in the US Anti-Cancer Drugs Market in Percentage, 2010-2013
Table 41: Revenues of Major players in the US Anti-Cancer Drugs Market in USD Million, 2010-2013
Table 42: Comparative Analysis of Major Players on the basis of Major Drugs, Number of Patents and Sales of Major Drugs in USD Million, 2013
Table 43: Global Research and Development Expenses of Pfizer in USD Million, 2009-2013
Table 44: Anti-cancer Drug Portfolio of Pfizer
Table 45: Pfizer Anti-cancer Drug Pipeline
Table 46: Global Research and Development Expenses of Novartis in USD Million, 2009-2013
Table 47: Anti-cancer Drug Profile of Novartis
Table 48: Novartis Cancer Drug Pipeline
Table 49: Global Research and Development Expenses of Roche in USD Million, 2009-2013
Table 50: Roche Anti-cancer Drug Portfolio
Table 51: Cancer Drug Pipeline of Roche
Table 52: Anti-cancer Drug Portfolio
Table 53: Anti-cancer Drug Pipeline
Table 54: Global Research and Development Expenses of Bristol Myers-Squibb in USD Million, 2009-2013
Table 55: Anti-cancer Drug Portfolio
Table 56: Cancer Drug Pipeline
Table 57: Global Research and Development Expenses of Amgen in USD Million, 2009-2013
Table 58: Anti-cancer Drug Portfolio of Amgen
Table 59: Cancer Drug Pipeline of Amgen
Table 60: Global Research and Development Expenses of Merck and Co. in USD Million, 2009-2013
Table 61: Anti-cancer Drug Portfolio of Merck & Co
Table 62: Cancer Drug Pipeline of Merck & Co.
Table 63: Global Research and Development Expenses of Celgene in USD Million, 2009-2013
Table 64: Anti-cancer Drug Portfolio of Celgene
Table 65: Cancer Drug Pipeline of Celgene
Table 66: Global Research and Development Expenses of Sanofi-Aventis in USD Million, 2009-2013
Table 67: Anti-cancer Drug Portfolio of Sanofi
Table 68: Cancer Drug Pipeline
Table 69: Global Research and Development Expenses of Eli-Lilly in USD Million, 2009-2013
Table 70: Anti-cancer Drug Portfolio
Table 71: Cancer Drug Pipeline
Table 72: Global Research Development Expenses of GalaxoSmith Kline in USD Million, 2011-2013
Table 73: GlaxoSmitheKline Anti-cancer Drug Profile
Table 74: Cancer Drug Pipeline of GlaxoSmitheKline
Table 75: Anti Cancer Drug Patent Expirations, 2013-2018
Table 76: Anti Cancer Drugs to Be Launched During 2013-2018
Table 77: Cause and Effect Relationship between Industry Factors and the US Anti-cancer Drug Market Prospects
Table 79: The US Anti Cancer Drug Industry Future Projections by Type of Cancer (Blood, Breast, Colon, Pancreatic, Lung and Brain Cancer) in USD Million, 2014-2018
Table 78: The US Anti Cancer Drug Industry Future Projections on the Basis of Number of Cancer Cases, 2014-2018
Table 80: Correlation Matrix of US Anti-Cancer Drug Market
Table 81: Regression Coefficients Output
Table 1: Average Cost of Treatment of Cancer in USD
Table 2: Anti-cancer Drugs in Pipeline
Table 3: Number of New Cancer Cases in US, 2008-2013
Table 4: Number of New Cases of Cancer in the US by Types of Cancers, 2008-2013
Table 5: Number of Anti Cancer Drugs Approved in the US, 2008-2013
Table 6: The US Anti Cancer Drug Market Segmentation by Types of Cancer by Industry Revenue in USD Million, 2010-2013
Table 7: Prices of Injectable Drugs in US by Cycle in USD, 2013
Table 8: Prices of Oral Drugs in US by Cycle in USD
Table 9: Cost of Cancer Therapies in USD, 2013
Table 10: Drugs Used for the Different Types of Cancer Therapies
Table 11: The US Anti Cancer Drug Market Segmentation by Generic and Patented Drugs on the Basis of Sales in USD Million and Contribution in Percentage, 2013
Table 12: Cost of Generic Drugs in USD, 2012
Table 13: Sales of Major Blood Cancer Drugs in USD Million, 2008-2013
Table 14: Prices of Major Blood Cancer Drugs per Cycle in USD, 2013
Table 15: Leukemia Survival by Stage in Percentage
Table 16: Approval and Expiry of Blood Cancer Drugs
Table 17: Sales of Major Breast Cancer Drugs in the US in USD Million, 2008-2013
Table 18: Prices of Major Breast Cancer Drugs per Cycle in USD, 2013
Table 19: Breast Cancer Survival by Stage in Percentage
Table 20: Approval and Expiry Periods of Major Breast Cancer Drugs in the US
Table 21: Sales of Major Colon Cancer Drugs in the US in USD Million, 2009-2013
Table 22: Prices of Major Colon Cancer Drugs per Cycle in USD, 2013
Table 23: Colon Cancer Survival Rate by Stage in Percentage
Table 24: Approvals and Expiry for Colon Cancer Drugs
Table 25: Sales of Major Brain Cancer Drugs in USD Million, 2009-2013
Table 26: Prices of Major Brain Cancer Drugs per Cycle in USD, 2013
Table 27: Brain Cancer Survival by Age in Percentage
Table 28: Approval and Expiry for Brain Cancer Drugs
Table 29: Sales of Major Lung Cancer Drugs in the US in USD Million, 2008-2013
Table 30: Prices of Major Lung Cancer Drugs per Cycle in USD, 2013
Table 31: The US Anti- Lung Cancer Drugs Market Segmentation by Small Cell Lung Cancer and Non Small Cell Lung Cancer on the Basis of Revenue Contribution in USD Million & Percentage, and Incidence Rates in the US, 2013
Table 32: Lung Cancer Survival by Stage
Table 33: Approval and Expiry Period of Major Lung Cancer Drugs in the US
Table 34: Sales of Major Pancreatic Cancer Drugs in USD Million, 2008-2013
Table 35: Prices of Major Pancreatic Cancer Drugs per Cycle in USD, 2013
Table 36: Exocrine Pancreatic Cancer Survival by Stage in Percentage
Table 37: Neuro-Endocrine Pancreatic Cancer Treated with Surgery Survival by Stage in Percentage
Table 38: Approval and Expiry Period of Major Pancreatic Cancer Drugs in the US
Table 39: US Anti-cancer Drug Market SWOT Analysis
Table 40: Market Shares of Major players by Revenue Contribution in the US Anti-Cancer Drugs Market in Percentage, 2010-2013
Table 41: Revenues of Major players in the US Anti-Cancer Drugs Market in USD Million, 2010-2013
Table 42: Comparative Analysis of Major Players on the basis of Major Drugs, Number of Patents and Sales of Major Drugs in USD Million, 2013
Table 43: Global Research and Development Expenses of Pfizer in USD Million, 2009-2013
Table 44: Anti-cancer Drug Portfolio of Pfizer
Table 45: Pfizer Anti-cancer Drug Pipeline
Table 46: Global Research and Development Expenses of Novartis in USD Million, 2009-2013
Table 47: Anti-cancer Drug Profile of Novartis
Table 48: Novartis Cancer Drug Pipeline
Table 49: Global Research and Development Expenses of Roche in USD Million, 2009-2013
Table 50: Roche Anti-cancer Drug Portfolio
Table 51: Cancer Drug Pipeline of Roche
Table 52: Anti-cancer Drug Portfolio
Table 53: Anti-cancer Drug Pipeline
Table 54: Global Research and Development Expenses of Bristol Myers-Squibb in USD Million, 2009-2013
Table 55: Anti-cancer Drug Portfolio
Table 56: Cancer Drug Pipeline
Table 57: Global Research and Development Expenses of Amgen in USD Million, 2009-2013
Table 58: Anti-cancer Drug Portfolio of Amgen
Table 59: Cancer Drug Pipeline of Amgen
Table 60: Global Research and Development Expenses of Merck and Co. in USD Million, 2009-2013
Table 61: Anti-cancer Drug Portfolio of Merck & Co
Table 62: Cancer Drug Pipeline of Merck & Co.
Table 63: Global Research and Development Expenses of Celgene in USD Million, 2009-2013
Table 64: Anti-cancer Drug Portfolio of Celgene
Table 65: Cancer Drug Pipeline of Celgene
Table 66: Global Research and Development Expenses of Sanofi-Aventis in USD Million, 2009-2013
Table 67: Anti-cancer Drug Portfolio of Sanofi
Table 68: Cancer Drug Pipeline
Table 69: Global Research and Development Expenses of Eli-Lilly in USD Million, 2009-2013
Table 70: Anti-cancer Drug Portfolio
Table 71: Cancer Drug Pipeline
Table 72: Global Research Development Expenses of GalaxoSmith Kline in USD Million, 2011-2013
Table 73: GlaxoSmitheKline Anti-cancer Drug Profile
Table 74: Cancer Drug Pipeline of GlaxoSmitheKline
Table 75: Anti Cancer Drug Patent Expirations, 2013-2018
Table 76: Anti Cancer Drugs to Be Launched During 2013-2018
Table 77: Cause and Effect Relationship between Industry Factors and the US Anti-cancer Drug Market Prospects
Table 79: The US Anti Cancer Drug Industry Future Projections by Type of Cancer (Blood, Breast, Colon, Pancreatic, Lung and Brain Cancer) in USD Million, 2014-2018
Table 78: The US Anti Cancer Drug Industry Future Projections on the Basis of Number of Cancer Cases, 2014-2018
Table 80: Correlation Matrix of US Anti-Cancer Drug Market
Table 81: Regression Coefficients Output
